secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2026-01-15T23:59:59+00:00
Accession:  0001193125-26-014231
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
--------------------------------------------------------------------------------

- Exclusive license to Future Pak for Mytesi (HIV/AIDS diarrhea) and Canalevia-CA1 (chemotherapy-induced diarrhea in dogs) in U.S.
- Jaguar receives $18M upfront ($16M at closing + $2M on conditions) and up to $20M in milestone/future payments.
- Jaguar retains manufacturing role; non-dilutive capital funds rare-disease pipeline (short bowel syndrome, MVID).
- Jaguar has buy-back option after 5 years or upon FDA approval of additional crofelemer indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000119312526014231/0001193125-26-014231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000119312526014231/jagx-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-014231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer